Impact of continuous positive airway pressure therapy for nonalcoholic fatty liver disease in patients with obstructive sleep apnea.
Chronic intermittent hypoxia
Continuous positive airway pressure
Nonalcoholic fatty liver disease
Obstructive sleep apnea
Transient elastography
Journal
World journal of clinical cases
ISSN: 2307-8960
Titre abrégé: World J Clin Cases
Pays: United States
ID NLM: 101618806
Informations de publication
Date de publication:
06 Jul 2021
06 Jul 2021
Historique:
received:
25
02
2021
revised:
28
04
2021
accepted:
07
05
2021
entrez:
26
7
2021
pubmed:
27
7
2021
medline:
27
7
2021
Statut:
ppublish
Résumé
Obstructive sleep apnea (OSA) has been suggested as an independent risk factor for nonalcoholic fatty liver disease (NAFLD), and continuous positive airway pressure (CPAP) is the first-line therapy for OSA. To clarify the efficacy of effective CPAP therapy on NAFLD of OSA patients by serum markers and transient elastography (TE) using FibroScan We prospectively enrolled 123 consecutive patients with OSA who met the indications for CPAP. Liver fibrosis and steatosis were assessed using TE. Before and after 6 mo of CPAP therapy, serum markers and TE were assessed for all patients. The mean usage rate of CPAP therapy for 6 mo was arbitrarily calculated in each patient and expressed as "mean compliance index" (m-CI). In 50 OSA patients with NAFLD, both aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were significantly decreased after 6 mo of CPAP therapy. Univariate analysis showed that decreased body weight (BW), decreased body mass index (BMI), decreased AST level, decreased hemoglobin A1c, and high m-CI were significantly related with improved ALT level. In multivariate regression model adjusted for quantities of BW change during 6 mo of CPAP therapy, high m-CI tended to improve ALT level ( Some NAFLD could be associated with chronic intermittent hypoxia due to OSA independent of BW changes. In those cases, adequate reoxygenation from effective CPAP therapy may improve NAFLD.
Sections du résumé
BACKGROUND
BACKGROUND
Obstructive sleep apnea (OSA) has been suggested as an independent risk factor for nonalcoholic fatty liver disease (NAFLD), and continuous positive airway pressure (CPAP) is the first-line therapy for OSA.
AIM
OBJECTIVE
To clarify the efficacy of effective CPAP therapy on NAFLD of OSA patients by serum markers and transient elastography (TE) using FibroScan
METHODS
METHODS
We prospectively enrolled 123 consecutive patients with OSA who met the indications for CPAP. Liver fibrosis and steatosis were assessed using TE. Before and after 6 mo of CPAP therapy, serum markers and TE were assessed for all patients. The mean usage rate of CPAP therapy for 6 mo was arbitrarily calculated in each patient and expressed as "mean compliance index" (m-CI).
RESULTS
RESULTS
In 50 OSA patients with NAFLD, both aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were significantly decreased after 6 mo of CPAP therapy. Univariate analysis showed that decreased body weight (BW), decreased body mass index (BMI), decreased AST level, decreased hemoglobin A1c, and high m-CI were significantly related with improved ALT level. In multivariate regression model adjusted for quantities of BW change during 6 mo of CPAP therapy, high m-CI tended to improve ALT level (
CONCLUSION
CONCLUSIONS
Some NAFLD could be associated with chronic intermittent hypoxia due to OSA independent of BW changes. In those cases, adequate reoxygenation from effective CPAP therapy may improve NAFLD.
Identifiants
pubmed: 34307562
doi: 10.12998/wjcc.v9.i19.5112
pmc: PMC8283589
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5112-5125Informations de copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors declare no conflicts of interest.
Références
J Gastroenterol. 2012 May;47(5):586-95
pubmed: 22328022
J Hepatol. 2016 Sep;65(3):589-600
pubmed: 27212244
J Epidemiol. 2011;21(3):161-8
pubmed: 21368452
Am J Med. 1999 Nov;107(5):450-5
pubmed: 10569299
Am J Physiol Gastrointest Liver Physiol. 2007 Oct;293(4):G871-7
pubmed: 17690174
Ultrasound Med Biol. 2016 Jan;42(1):104-9
pubmed: 26385053
Sleep. 2015 Oct 01;38(10):1583-91
pubmed: 26085300
J Gastroenterol. 2011 Jan;46 Suppl 1:63-9
pubmed: 20844903
Eur Heart J. 2004 May;25(9):735-41
pubmed: 15120883
Sleep Breath. 2017 May;21(2):461-467
pubmed: 27957696
Ultrasound Med Biol. 2003 Dec;29(12):1705-13
pubmed: 14698338
J Clin Lab Anal. 2016 Sep;30(5):672-6
pubmed: 26857805
J Clin Sleep Med. 2018 Jan 15;14(1):133-139
pubmed: 29151428
BMJ. 2019 Oct 8;367:l5367
pubmed: 31594780
Gastroenterology. 2011 Jan;140(1):124-31
pubmed: 20858492
Lancet. 2005 Mar 19-25;365(9464):1046-53
pubmed: 15781100
Respiration. 2009;78(2):141-6
pubmed: 18984944
Hepatology. 2007 Apr;45(4):1007-13
pubmed: 17393512
Eur Respir J. 2013 Mar;41(3):601-9
pubmed: 22743670
Clin Respir J. 2018 Feb;12(2):373-381
pubmed: 27614004
Pathol Res Pract. 1994 Oct;190(9-10):910-9
pubmed: 7899140
Respir Care. 2012 Feb;57(2):238-43
pubmed: 21762553
N Engl J Med. 2011 Dec 15;365(24):2277-86
pubmed: 22168642
Vasc Health Risk Manag. 2008;4(6):1327-35
pubmed: 19337546
Am J Med. 2003 Apr 1;114(5):370-6
pubmed: 12714126
Am Rev Respir Dis. 1993 Apr;147(4):887-95
pubmed: 8466125
Clin Liver Dis. 2019 May;23(2):363-382
pubmed: 30947882
Lung. 2010 Aug;188(4):301-7
pubmed: 20066542
J Clin Biochem Nutr. 2009 Nov;45(3):335-40
pubmed: 19902025
J Pediatr. 2018 Jul;198:67-75.e1
pubmed: 29752170
Aliment Pharmacol Ther. 2011 Aug;34(3):274-85
pubmed: 21623852
Clin Cardiol. 2014 Jan;37(1):57-65
pubmed: 24567977
Nutrients. 2017 Jul 26;9(8):
pubmed: 28933748
Eur Respir J. 2012 Oct;40(4):913-8
pubmed: 22267762
Gastroenterology Res. 2018 Jun;11(3):252-259
pubmed: 29915639
PLoS One. 2013;8(1):e49286
pubmed: 23326306
Respir Care. 2013 Sep;58(9):1467-73
pubmed: 23431305
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Sleep Breath. 2018 Dec;22(4):963-972
pubmed: 29327118
Respirology. 2016 Feb;21(2):378-85
pubmed: 26567858
Ann Med. 2011 Dec;43(8):617-49
pubmed: 21039302
N Engl J Med. 2010 Sep 30;363(14):1341-50
pubmed: 20879883
Ultrasound Med Biol. 2010 Nov;36(11):1825-35
pubmed: 20870345
Eur Arch Otorhinolaryngol. 2018 Feb;275(2):587-594
pubmed: 29224042
J Clin Sleep Med. 2018 Aug 15;14(8):1315-1322
pubmed: 30092894
Hepatology. 2003 Aug;38(2):518-26
pubmed: 12883497
Thorax. 2012 Dec;67(12):1081-9
pubmed: 22561530